Jan 30, 2025 / 10:00AM GMT
Britt Meelby Jensen - Ambu A/S-Chief Executive Officer - Member of the Executive Board
Hello, everyone, and welcome to this call where I, together with my colleague, Henrik Skak Bender, our CFO, I'm Britt Meelby Jensen, the CEO. And together, we will present the Q1 '24-'25 results from Ambu.
Let me start with the key messages from this first quarter, where we had a strong start to our '24-'25 financial year. We continued with very strong organic revenue growth, posting 19.5% growth and also an increase in our profitability with an EBIT margin of 16.1%. Looking at our key focus area, our Endoscopy Solutions, we saw a strong growth in both segments that we report on. Our Pulmonology business grew by 17.7% in the quarter, and we had a growth in Urology, ENT and GI combined of 23.9%.
Also, we continue to be highly focused on innovation, and this is where we were excited to announce the registration of our new airway management solution, SureSight, our video laryngoscopy solution that I'll come back and talk about later in this call.
And
Q1 2025 Ambu A/S Earnings Call Transcript
Jan 30, 2025
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers